PA-EXONE
24.6.2020 14:02:10 CEST | Business Wire | Press release
The ExOne Company (Nasdaq: XONE), the global leader in industrial sand and metal 3D printers using binder jetting technology, today announced the launch of its updated Quick Ship metal 3D printing services, featuring a new digital quoting tool and materials.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200624005137/en/
ExOne Quick Ship will now add the popular stainless steels 316L and 17-4PH to the list of materials offered through instant quoting, with delivery times of 10-15 business days, depending on number of units requested, part size, and other requirements.
“After two years of supplying thousands of 316L and 17-4 parts to select industrial customers, our updated Quick Ship services will now allow any customer to easily acquire and evaluate affordable single-alloy parts 3D printed with binder jetting,” said John Hartner, ExOne CEO.
A new Quick Ship online dashboard, available at www.exone.com/quickship , will allow customers to upload a qualifying digital design file for an instant quote and purchase, as well as create an account to track projects. More than 30 file types are accepted including STL and STP files.
Quick Ship parts will be 3D printed at ExOne’s metal production facility outside Pittsburgh, which has been binder jetting metal parts for more than two decades. It’s home to a fleet of more than two dozen metal 3D printers producing parts for prototype, low-volume, and serial production projects.
Quick Ship Service Represents Critical Progress
Binder jet 3D printing is a method of additive manufacturing in which an industrial printhead deposits a liquid binder onto a thin layer of powdered particles, layer by layer, until an object is formed. Parts printed in metal powders are then sintered in a furnace to fuse the particles.
In development since 1996, ExOne metal binder jet systems are capable of producing parts in more than 20 metals, ceramics and composite materials today. The technology is viewed as a disruptive and sustainable production method, largely because of its high speed, relatively low cost and material flexibility, among other benefits.
“The launch of Quick Ship services for single-alloy metals represents a key step forward in our development of metal binder jetting, and one that signifies our continued confidence in this technology,” said Rick Lucas, ExOne Chief Technology Officer and VP of New Markets. “We also have plans to expand the number of material offerings and size of printable parts in our Quick Ship services by year-end.”
Featured Quick Ship Metal 3D Printers
Quick Ship parts in 316L and 17-4PH will be 3D printed on ExOne’s Innovent+ and X1 25Pro metal 3D printing systems. Both machines feature ExOne’s exclusive Triple ACT system, an advanced compaction technology that delivers industry-leading density and repeatability in metal binder jetting. ExOne 3D printers with Triple ACT are capable of delivering sintered dimensional accuracy of +/- 2.5% on a first print run, with better results possible after additional sintering optimization.
ExOne will continue to offer its popular 316 and 420 materials infiltrated with bronze on its classic M-Flex and R2 metal 3D printing models, which have been in operation since 2013 and 2003, respectively. Infiltrated parts, which offer a variety of functionality and finish benefits, are typically shipped within 10 business days.
Other Materials Available Through Premium Quote
Metal, ceramic and composite materials not available through ExOne’s Quick Ship service will continue to be offered on a limited basis through ExOne’s Premium Quote service. Delivery times will vary based on the project details.
The full list of materials printable on ExOne 3D printing systems can be viewed at www.exone.com/metalmaterial . Materials such as M2 Tool Steel and Inconel 718 are available for quoting, and quote requests may depend on material availability.
About ExOne
ExOne is the pioneer and global leader in binder jet 3D printing technology. Since 1995, we’ve been on a mission to deliver powerful 3D printers that solve the toughest problems and enable world-changing innovations. Our 3D printing systems quickly transform powder materials — including metals, ceramics, composites and sand — into precision parts, metalcasting molds and cores, and innovative tooling solutions. Industrial customers use our technology to save time and money, reduce waste, improve their manufacturing flexibility, and deliver designs and products that were once impossible. As home to the world’s leading team of binder jetting experts, ExOne also provides specialized 3D printing services, including on-demand production of mission-critical parts, as well as engineering and design consulting. Learn more about ExOne at www.exone.com
or on Twitter at @ExOneCo. We invite you to join with us to #MakeMetalGreen™.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200624005137/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom